Sacra estimates that Oura generated $1B in revenue in 2025, up 100% year-over-year from $500M in 2024.

The revenue mix breaks down to approximately 80% hardware and 20% subscription revenue. In 2024, Oura sold 1.3M rings, generating roughly $390M in hardware revenue, while doubling its paying subscriber base to 2M users contributing approximately $110M in subscription revenue at $6 per month.

The company's expansion into retail channels including Target and Amazon in April 2024, combined with the launch of the Oura Ring 4 in October, drove the strong hardware performance in the second half of the year. More than half of all 5.5M rings ever sold were sold in 2024 alone, reflecting the step-change in distribution scale that year.

In October 2025, Oura raised $900M led by Fidelity at an approximately $11B valuation, more than double its December 2024 $5.2B round. The round included participation from ICONIQ, Whale Rock, and Atreides, with proceeds directed toward AI and production innovation, new health features, and global distribution. Alongside the raise, David Shuman was named chair of the board, succeeding Eurie Kim, and Wen Hsieh was nominated as a new board director. In September 2025, Oura also secured a $250M revolving credit facility arranged by JPMorgan, Goldman Sachs, Bank of America, Barclays, Citi, and Wells Fargo.

In January 2026, Bloomberg reported that Oura was planning a tender offer for existing investors at roughly a 25% discount to the Series E round price, providing early-investor liquidity while enabling the company to remain private longer. This was a Bloomberg report, not an official company announcement.

Oura last raised $200M in a Series D round in December 2024, valuing the company at $5.2B. That round was led by Fidelity Management & Research Company with participation from Dexcom, which also made a separate $75M strategic investment to support the companies' glucose monitoring integration.

The company has raised approximately $1.5B in total capital since 2015. Previous investors include The Chernin Group, Elysian Park Ventures, Temasek, JAZZ Venture Partners, Eisai, and Forerunner Ventures.

Oura is a titanium smart ring that continuously monitors physiological data through 18 light paths, dual temperature sensors, and motion tracking sensors, transmitting data via Bluetooth to a mobile app that provides sleep, readiness, and activity insights. The ring weighs 4 grams, lasts 6-8 days on a single charge, and comes in 6 finishes across sizes 4-15. The lineup also includes zirconia ceramic versions in four additional finishes (midnight, petal, tide, cloud), broadening material and aesthetic options beyond the core titanium offering.

Users wear the ring 24/7 and receive three daily scores: Sleep (tracking sleep stages, duration, and quality), Readiness (measuring recovery and resilience), and Activity (monitoring movement and workouts).

The ring automatically detects over 40 types of activities and switches to high-frequency 250 Hz sampling during sleep for detailed sleep stage analysis. Women can enable cycle tracking features that use temperature trends to predict ovulation and menstruation windows, with cycle phase and prediction data available from as little as one night of sleep data rather than the prior 60-night minimum. Oura has extended women's health coverage across the full reproductive lifespan through Pregnancy Insights and Perimenopause Check-In (launched August 2025), with clinical integrations spanning Midi Health, Evernow, Maven Clinic, and Progyny, positioning Oura as a data layer within the women's healthcare ecosystem. The company has also built a proprietary large language model purpose-built for women's health (launched February 2026), hosted on Oura-controlled infrastructure with conversations never shared or sold; it launched initially in Oura Labs.

The Oura app serves as the primary interface, featuring three main sections: Today for daily scores, Vitals for physiological trends including resting heart rate and heart rate variability, and My Health for long-term tracking and guided content. The current app design (updated October 2025) added Cumulative Stress tracking, expanded Cycle Insights to a 12-month view, and launched an investigational Blood Pressure Profile study in Oura Labs. Oura Advisor — an AI health coach that answers health questions using personal data — is available to all members; in internal surveys, 60% of users said it helped them understand metrics better, 87% said it accurately remembered their health goals, and 56% said it helped turn insights into actions.

Oura has deepened its metabolic health offering through Meals and Glucose (launched May 2025), integrating meal photo logging with Stelo by Dexcom glucose sensor data inside the Oura app. Health Panels, also part of the current platform, link 50 blood biomarkers to ring data using Quest Diagnostics labs, with booking available across approximately 2,000 U.S. locations. Together, these features extend Oura from continuous biometric monitoring into a broader preventive health platform that connects wearable data with lab diagnostics and dietary context.

The ring's finger placement provides significantly stronger physiological signals compared to wrist-based devices, enabling more accurate measurements and early detection capabilities like illness prediction through subtle changes in baseline metrics. Multi-ring device support extends continuity further, and a charging case holds up to five full charges, reducing charging as a friction point to sustained wear.

Oura has pursued an active acquisition strategy to expand platform capabilities. The company acquired Doublepoint, a Helsinki-based startup specializing in AI-driven biometric gesture recognition, with all four founders joining; Oura frames voice and gesture as the next interaction layer for wearable AI, though commercial availability of gesture features has not been announced. The company also acquired Galen AI (acquired April 2026), a platform that unifies medical records, lab results, medications, and wearable data into a connected health companion, extending Oura's capability to integrate structured clinical data alongside continuous biometric monitoring.

Oura operates a B2C hardware-plus-subscription model that combines one-time ring sales with recurring monthly memberships. The company sells rings directly through its website and retail partners like Target, Amazon, and Apple Stores, with titanium hardware priced at $299-399 and a ceramic version at $499. The core monetization comes from the required $6 monthly Oura Membership, which unlocks all health insights, personalized recommendations, and app features beyond basic daily scores.

This dual revenue stream creates a flywheel where hardware sales drive subscription growth, while subscription revenue funds continued product development and AI improvements that justify the ongoing fee. The subscription model generates predictable recurring revenue with high gross margins, while hardware sales provide upfront cash flow and customer acquisition. The business model benefits from strong retention dynamics, as users who invest in the hardware and develop daily habits around their health data tend to maintain subscriptions long-term — retention at the 12-month mark sits in the high 80s, with the fastest-growing segment being women in their early twenties.

Beyond the core ring and membership, Oura has introduced adjacent paid products that deepen monetization per member: Health Panels at $99 link 50 blood biomarkers to ring data via Quest Diagnostics labs across ~2,000 U.S. locations, and Stelo by Dexcom glucose sensors can be purchased for $99 and paired directly with the Oura app. These add-ons extend revenue per user without requiring subscription price increases.

Oura's go-to-market strategy has evolved from direct-to-consumer to omnichannel, now spanning 4,000 retail stores and 1,000 API partners. The company also operates Oura for Business, providing rings and analytics dashboards to enterprise customers including the U.S. Department of Defense — its largest enterprise customer — with tens of thousands of rings deployed across the defense sector since 2019. To support this defense business, Oura is establishing U.S. manufacturing operations in Fort Worth, Texas (opening 2026), creating a domestically sourced supply chain for government and enterprise customers.

Samsung entered the smart ring market with the Galaxy Ring, priced at $399 with no subscription fee and integration into the Samsung Health ecosystem. Samsung's approach leverages their smartphone dominance and component manufacturing scale to offer lifetime insights without recurring fees, potentially resetting consumer price expectations. Apple remains a looming threat with rumored ring development and patents showing health sensor integration, though analysts don't expect a launch until 2028-2030.

RingConn, Ultrahuman, and Circular have attacked Oura's subscription model by offering comparable hardware at $199-349 with no monthly fees. Oura has used its patent portfolio aggressively to defend this flank: its dispute with RingConn was resolved through a licensing agreement under which RingConn continues selling its rings and app while paying royalties to Oura, with OMATE receiving access to part of Oura's patent portfolio under a separate agreement. The ITC issued exclusion and cease-and-desist orders against Ultrahuman, barring import and sale of infringing rings in the U.S. (effective October 2025), though Ultrahuman may redesign its product to work around the ruling.

Apple Watch, Fitbit, Garmin, and WHOOP continue to dominate the broader wearables market with established ecosystems and expanding health features. WHOOP's subscription-first model at $30 monthly targets serious athletes with detailed recovery analytics, while Apple Watch's integration with iPhone and expanding health sensors creates a comprehensive platform. These devices offer broader functionality beyond health tracking, though they require daily charging and may be less comfortable for sleep monitoring.

Oura has systematically expanded from sleep tracking into readiness, stress monitoring, metabolic health, and cardiovascular research. The current app includes Cumulative Stress tracking and an investigational Blood Pressure Profile study in Oura Labs, pointing toward future cardiovascular monitoring capabilities. Heart health and healthy aging represent additional expansion opportunities, with the ring's continuous monitoring enabling early detection of cardiovascular changes.

Oura has built the most comprehensive women's health feature set in consumer wearables, spanning menstrual cycle tracking, fertility, pregnancy, and perimenopause. Pregnancy Insights and Perimenopause Check-In (launched August 2025), paired with clinical integrations with Midi Health, Evernow, Maven Clinic, and Progyny, position Oura as a data layer within the women's healthcare ecosystem rather than a standalone device. This moat deepens further with a proprietary women's health large language model (launched February 2026), hosted on Oura-controlled infrastructure, built specifically for this population.

The enterprise market through Oura for Business addresses the $60B corporate wellness opportunity, with 200+ organizations including the US military using rings for team health monitoring. Oura also serves elite athletes as the Official Wearable of Team USA and the LA28 Olympic & Paralympic Games, supporting athletes across the 2026 and 2028 Games with rings for recovery, sleep, and wellbeing tracking. Healthcare providers represent another expansion vector, as Oura pursues FDA diagnostic clearance and clinical partnerships for remote patient monitoring. Health Panels, which link 50 blood biomarkers to ring data via Quest Diagnostics, extend Oura further into preventive healthcare by adding lab testing to its data platform.

Oura has expanded its retail footprint across four new markets — Australia/New Zealand, India, Mexico, and the UAE (launched March 2026) — through local distribution partners including JB Hi-Fi, Harvey Norman, Noel Leeming, Croma, Amazon, Liverpool, Amazon.ae, Go Sport, Virgin Megastore, and Dubai Duty Free. The company is also prioritizing Western European markets including the UK, Germany, France, and Italy, leveraging retail partnerships and localized marketing. Asia-Pacific represents a longer-term opportunity with 30%+ projected growth through 2030.

CEO Tom Hale has identified M&A as an explicit pillar of Oura's growth strategy. The company has completed five acquisitions — Sparta Science, Veri, Proxy, Doublepoint, and Galen AI — each targeting a distinct capability gap: performance analytics, metabolic health, access control, biometric gesture-based AI interaction, and clinical data unification (medical records, labs, and medications integrated with wearable data), respectively.

Platform dependence: Oura's business model relies heavily on smartphone app distribution through Apple and Google's app stores, creating vulnerability to platform policy changes, commission increases, or competitive restrictions. Any limitations on health data collection or subscription billing could significantly impact Oura's core revenue streams.

Hardware commoditization: As smart ring technology matures and manufacturing costs decline, the hardware component of Oura's business faces margin pressure from low-cost competitors offering similar sensor capabilities. The company's ability to maintain premium pricing depends on continued software differentiation and brand strength.

Subscription fatigue: Consumer resistance to subscription services is growing across categories, and Oura's requirement for ongoing payments to access health insights may face pushback as competitors offer similar features without monthly fees.